Pair Name | Oleuropein, Cisplatin | ||
Phytochemical Name | Oleuropein (PubChem CID: 5281544 ) | ||
Anticancer drug Name | Cisplatin (PubChem CID: 5702198 ) | ||
Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
Pair Name | Oleuropein, Cisplatin | |||
Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
Gene Regulation | Up-regulation | Expression | CASP3 | hsa836 |
Down-regulation | Expression | MMP7 | hsa4316 | |
Down-regulation | Expression | NGF | hsa4803 | |
In Vitro Model | Hep-G2 | Hepatoblastoma | Homo sapiens (Human) | CVCL_0027 |
Result | Our results showed for the first time that the anti-tumor activity of oleuropein against HCC could be attributed to influencing the pro-NGF/NGF balance via affecting MMP-7 activity without affecting the gene expression of NGF. Concurrent treatment with both oleuropein and cisplatin could lead to more effective chemotherapeutic combination against HCC. |
Pair Name | Oleuropein, Cisplatin | |||
Disease Info | [ICD-11: 2C73] | Ovarian cancer | Investigative | |
Gene Regulation | Down-regulation | Expression | BCL2 | hsa596 |
Up-regulation | Expression | CDKN1A | hsa1026 | |
Up-regulation | Expression | GDE1 | hsa51573 | |
Down-regulation | Expression | MCL1 | hsa4170 | |
Up-regulation | Expression | TNFRSF10B | hsa8795 | |
Up-regulation | Expression | TP53 | hsa7157 | |
In Vitro Model | A2780 | Ovarian endometrioid adenocarcinoma | Homo sapiens (Human) | CVCL_0134 |
A2780/CP70 | Ovarian endometrioid adenocarcinoma | Homo sapiens (Human) | CVCL_0135 | |
Result | These data revealed that oleuropein regulated the expression of the above-mentioned miRNAs in ovarian cancer cells, which potentially resulted in apoptosis induction, cell proliferation inhibition, and cisplatin resistance decline in ovarian cancer cells. To confirm the results of this study, it is suggested that similar experiments be performed in animal models of ovarian cancer. |
No. | Title | Href |
---|---|---|
1 | Oleuropein potentiates anti-tumor activity of cisplatin against HepG2 through affecting proNGF/NGF balance. Life Sci. 2018 Apr 1;198:87-93. doi: 10.1016/j.lfs.2018.02.027. | Click |
2 | Oleuropein reduces cisplatin resistance in ovarian cancer by targeting apoptotic pathway regulators. Life Sci. 2021 Aug 1;278:119525. doi: 10.1016/j.lfs.2021.119525. | Click |